Literature DB >> 3108905

Cyclooxygenase and lipoxygenase metabolites during platelet aggregation: quantitative measurement by negative ion chemical ionization--gas chromatography/mass spectrometry.

E Malle, J Nimpf, H J Leis, H Wurm, H Gleispach, G M Kostner.   

Abstract

This study was aimed at investigating systematically the aggregation of human gel filtered platelets induced by various physiological stimuli such as thrombin (0.25 U/ml), collagen (2 micrograms/ml), a mixture of thrombin and collagen, and ADP (2-5 microM). For quantitative measurement of TXB2, PGF2 alpha and 12-HETE, negative ion chemical ionization-gas chromatography/mass spectrometry using stable isotope dilution was applied. Stimulation by thrombin, collagen and the combined agonists resulted in an increase of TXB2 (up to 54 ng/1 X 10(8) platelets) and 12-HETE (up to 44 ng/1 X 10(8) platelets) during platelet aggregation. The stimulation with ADP showed only little increase of these metabolites and this only during the second wave of aggregation. Very little amounts of PGF2 alpha were produced during thrombin stimulated aggregation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108905     DOI: 10.1016/0262-1746(87)90059-x

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  3 in total

1.  Effect of cytochrome P-450 inhibitors econazole, bifonazole and clotrimazole on prostanoid formation.

Authors:  H C Köfeler; G Fauler; W Windischhofer; H J Leis
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  On the inhibition of prostanoid formation by SK&F 96365, a blocker of receptor-operated calcium entry.

Authors:  H J Leis; D Zach; E Huber; L Ziermann; H Gleispach; W Windischhofer
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

3.  Inhibition of prostanoid formation in intact cells by 2,5-di-(tert-butyl)-1,4-benzohydroquinone, a blocker of Ca(2+)-ATPases.

Authors:  H J Leis; D Zach; E Huber; L Ziermann; H Gleispach; W Windischhofer
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.